IOVA Overview
Upcoming Projects (IOVA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IOVA)
-
A second look: Discussing current commercial use of Amtagvi (lifileucel) from Iovance in previously treated melanoma
Ticker: IOVA
Executed On: Apr 25, 2025 at 03:00 PM EDT -
Discussing current commercial use of Amtagvi (lifileucel) from Iovance in previously treated melanoma
Ticker: IOVA
Executed On: Apr 24, 2025 at 02:00 PM EDT -
Discussing the use of Amtagvi (lifileucel) in previously treated melanoma
Ticker: IOVA
Executed On: Oct 21, 2024 at 12:00 PM EDT -
Advancing Melanoma Treatment: Insights into Iovance Biotherapeutics, Inc.'s Lifileucel and Pembrolizumab Combination, following ASCO
Tickers: IOVA, BMY
Executed On: Jun 14, 2024 at 07:20 AM EDT -
Discussing Iovance's TIL therapy AMTAGVI (lifileucel) recently FDA approved for unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody.
Ticker: IOVA
Executed On: Feb 22, 2024 at 12:00 PM EST -
A Second View: Discussing the potential of Iovance's TIL therapy, lifileucel, and the results from the Phase 2 study in patients with melanoma presented at the ESMO 2023 conference.
Ticker: IOVA
Executed On: Jan 04, 2024 at 05:00 PM EST -
Two Week Delay: Survey on Metastatic Cutaneous Melanoma and TIL Therapy & HSV Therapy
Ticker: IOVA
Executed On: Jan 02, 2024 at 04:15 PM EST -
Discussing the potential of Iovance's TIL therapy, lifileucel, and the results from the Phase 2 study in patients with melanoma presented at the ESMO 2023 conference.
Ticker: IOVA
Executed On: Nov 03, 2023 at 04:00 PM EDT -
Discussing therapeutics in development for melanoma including Moderna/Merck's mRNA-4157 cancer vaccine and Iovance Biotherapeutics' TIL therapy, lifileucel.
Tickers: MRNA, IOVA, MRK
Executed On: May 09, 2023 at 10:30 AM EDT -
Examining the potential of Iovance's tumor infiltrating lymphocyte (TIL) therapy, lifileucel, in advanced unresectable or metastatic melanoma
Ticker: IOVA
Executed On: Apr 13, 2023 at 03:00 PM EDT
Expired Projects (IOVA)
-
Analyzing Iovance's lifileucel Compared to Instil Bio’s main candidate, ITIL-168, in Melanoma
Tickers: IOVA, TIL
Execute By: Jun 25, 2021
Upcoming & Overdue Catalysts (IOVA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IOVA)
Strategic Initiatives (IOVA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
